¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2022-05-20

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2022-05-20
±³À°ÀÏÀÚ : 2022-05-20
±³À°Àå¼Ò : °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B ¿Ü 1°³·ë  
±³À°ÁÖÁ¦ : Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇÑ¿µ»óÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ  
´ã´çÀÚ : ÁÖÇýÁ¤
¿¬¶ôó : 02-465-9070  
À̸ÞÀÏ : office@intervention.or.kr      
±³À°Á¾·ù : ¿µ»óÀÇÇаúÀÇ»çÇÐ
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í »çÀüµî·Ï-Á¤È¸¿ø50000¿ø, Àü¹®ÀÇ100000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 30000¿ø, ÁØȸ¿ø¹×±âŸ 50000¿ø/ÇöÀåµî·Ï-Á¤È¸¿ø70000¿ø, Àü¹®ÀÇ120000¿ø, Àü°øÀÇ(¿¬È¸ºñ³³ºÎÀÚ)¹«·á, Àü°øÀǹװøº¸ÀÇ 50000¿ø, ÁØȸ¿ø¹×±âŸ 70000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:00~13:07 Factors for successful transvenous retrograde thoracic duct cannulation  ±èÇüõ(°Ç¾çÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:07~13:10 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:10~13:17 To evaluate technical success and safety of a planned percutaneous transhepatic approach (PPTA) to the thoracic duct  Á¤±¸¼º(õ¾ÈÃ湫º´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:17~13:20 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:20~13:27 Efficacy and Safety of Large-Bore Uncovered Stents for Malignant Superior Vena Cava Syndrome  ÃÖ»ó¸²(Áß¾Ó´ëÇб³ ±¤¸íº´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:27~13:30 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:30~13:37 Deep learning quantification of degree of AVF stenosis and prediction of 6months primary patency based on AVF shunt sound  ¹®¼º¸ð(¿¬¼¼ÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:37~13:40 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:40~13:47 The Usefulness of Catheter Length Prediction Formula Using Only the Anteroposterior Chest Radiograph and Wireless Ultrasound System in Bedside PICC Insertion: A Single Center Experience for Patients in COVID-19 Isolation Ward  ¹Ú¼ºÁØ(°í·ÁÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:47~13:50 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:50~13:57 Effectiveness of two sessions of catheter-directed sclerotherapy for ovarian endometrioma  ½ÅÁöÈÆ(¿ï»êÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:57~14:00 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:00~14:15 Vessel preparation: when and how  ±ÇÁØÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:15~14:30 Drug coated balloons: are there any differences?  ±è¹Î¿í(º¸¶ó¸Åº´¿ø) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:30~14:45 Stents: what are the remaining roles of stents in SFA in an era of drug technology  Á¶¼ö¹ü(ÀÌÈ­ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 14:45~15:00 BTK angioplasty for limb salvage: how I do it  ¹Ú»ó¿ì(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:00~15:15 Is DVA a viable option for &quotno option" limb or &quotdesert foot"  ±Ç¿äÇÑ(¾ÆÁÖÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:15~15:20 Discussion  () 
È޽Ġ05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:20~15:40 Coffee break  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:40~15:55 Clinical evaluation of varicose vein patients  Á¶ÁøÇö(°­µ¿°æÈñ´ëº´¿ø) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 15:55~16:10 Radiological evaluation of varicose vein patients  ±Ç·Á¹Î(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:10~16:25 Update in varicose vein intervention  ÀÌÀ±ÇÐ(¼­¿ï¼±Ç÷°üÅëÁõ¼¾ÅÍ) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:25~16:45 Various devices for endovenous procedure for varicose vein (case based)  È²ÁøÈ£(°Ç±¹ÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:45~16:50 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 16:50~17:20 What¡¯s new  ½ÉÀçÇö, ÀÌ¿ì¶÷(Boston, COOK) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:00~13:07 Catheter-directed sclerotherapy versus Surgical excision with subsequent Dienogest therapy for the treatment of ovarian endometrioma: Propensity score analyses of short-term outcomes  ÀÌÀçȯ(ºÐ´ç¼­¿ï´ëÇб³º´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:07~13:10 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:10~13:17 Modified surgical drain-guided percutaneous catheter drainage for postoperative fluid collection in inaccessible locations  ÀÌÇü³²(¼øõÇâÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:17~13:20 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:20~13:27 Pathologic response of single hepatocellular carcinoma treated with balloon-occluded transcatheter arterial chemoembolization  ±èÁöÈÆ(¿ï»êÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:27~13:30 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:30~13:37 Percutaneous nephrostomy for complex renal stone : Percutaneous renal access behind a stone  ¾ÈÀç°æ(°æ»óÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:37~13:40 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:40~13:47 Comparison of technical feasibility and clinical outcomes between 6Fr and 8Fr Double J Stents for Ureteral Obstruction  ¿ÀâÈÆ(°í·ÁÀÇ´ë) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:47~13:50 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 13:50~13:57 Outcomes of percutaneous transhepatic treatment for bile duct stones a multicenter retrospective study in 2431 patients  Á¤±Ô½Ä(¿ï»êº´¿ø) 
Åä·Ð 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 3Ãþ 300B 13:57~14:00 Discussion  () 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 14:00~14:20 Hemodynamics of HCC  Á¤Áø¿í(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 14:20~14:40 Drug preparation - lipiodol and embolic materials  ±èȿö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 14:40~15:00 Superive TACE  ÀÌÀÎÁØ(±¹¸³¾Ï¼¾ÅÍ) 
±³À°½Ã°£ 05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 15:00~15:20 Arterial anatomy - What to know during TACE  ±è°æ¹Î(¿¬¼¼ÀÇ´ë) 
È޽Ġ05-20 °æÁÖÈ­¹éÄÁº¥¼Ç¼¾ÅÍ 2Ãþ 205+206 15:20~15:40 Coffee break  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÀÎÅͺ¥¼Ç¿µ»óÀÇÇÐȸ Á¦31Â÷ Á¤±âÇмú´ëȸ(1ÀÏÂ÷) : 2022-05-20""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑÁ¶Çöº´ÇÐȸ Quality of life as a treatment goal in schizophrenia : 2022-05-20
´ÙÀ½±Û (¿Â¶óÀÎ) 2022³â 5¿ù ´ëÇÑÇÙÀÇÇÐȸ ¿ù·ÊÁý´ãȸ ¹× Ãá°è¿µÈ£³²Áý´ãȸ : 2022-05-20
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
21135 °æ±â Á¦10Â÷ ¿¬¼¼ÀÇ´ë ¼Ò¾Æû¼Ò³â°ú Áö¿ªÀÇ»ç Áý´ãȸ : 2024-07-31 0 16 2024-06-19
21134 °æ±â 2024 Çѱ¹¼ö¸éÇÐȸ ÇÏ°èÇмú´ëȸ : 2024-07-26 0 32 2024-06-19
21133 ¼­¿ï 2024³â ´ëÇÑÇǺη¹ÀÌÀúÇÐȸ Á¦25ȸ Çмú´ëȸ : 2024-07-21 0 23 2024-06-19
21132 ¼­¿ï ´ëÇÑÀÓ»ó¾Ï´ë»çÀÇÇÐȸ 2024³â Ãß°èÇмú´ëȸ IVC¿Í Detox : 2024-07-21 0 14 2024-06-19
21131 ´ë±¸ ´ë±¸°æºÏ³»°úÇÐȸ 2024³â Á¤±âÇмú´ëȸ : 2024-07-21 0 15 2024-06-19
21130 Á¦ÁÖ Á¦13ȸ ´ëÇѳ»ºÐºñÇÐȸ Á¦ÁÖÁöȸ ¿¬¼ö°­Á : 2024-07-20 0 7 2024-06-19
21129 ±¤ÁÖ Á¦225Â÷ ´ëÇÑ¿µ»óÀÇÇÐȸ ±¤ÁÖÀü³²Áöȸ ¿¬¼ö°­Á : 2024-07-16 0 12 2024-06-19
21128 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ Á¦3ȸ ÃÊÀ½ÆÄ ½ÇÀü ¾ÆÄ«µ¥¹Ì : 2024-07-15 0 17 2024-06-19
21127 ¼­¿ï 2024 ¼¼ºê¶õ½ºº´¿ø ¼ÒÈ­±âÇÐ ¿¬¼ö°­Á : 2024-07-14 0 14 2024-06-19
21126 ¼­¿ï (¿Â¶óÀÎ) 2024³â ´ëÇÑôÃß¿µ»óÀÇÇÐȸ Á¤±â¿¬¼ö°­Á : 2024-07-14 0 9 2024-06-19
21125 ¼­¿ï Á¦29Â÷ Ưº°¿¬¼ö°­Á – »êºÎÀΰú Áúȯ óġÀÇ ÃֽŠÁö°ß : 2024-07-14 0 16 2024-06-19
21124 °­¿ø 2024³â ´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ °­¿øÁöȸ ¿¬¼ö°­Á : 2024-07-14 0 10 2024-06-19
21123 ¼­¿ï 2024³â ´ëÇѹ̼¼¼ö¼úÇÐȸ Ãá°è ¹Ì¼¼¼ö¼ú ¿öÅ©¼ó : 2024-07-14 0 15 2024-06-19
21122 ¼­¿ï Çѱ¹¹é³»Àå±¼Àý¼ö¼úÇÐȸ 2024 KSCRS Annual Symposium(2ÀÏÂ÷) : 2024-07-14 0 7 2024-06-19
21121 ¼­¿ï Á¦8ȸ ÀüÀÓÀÇ Àü°øÀÇ °³¿øÀǸ¦ À§ÇÑ °£Áúȯ ¿¬¼ö°­Á : 2024-07-14 0 12 2024-06-19
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷